Table 2 Patients’ characteristics

Total number, n (%)

179 (100)

56 (31)

112 (63)

6 (3)

5 (3)

Age, y

73 ± 9

73 ± 7

71 ± 9

68 ± 21

72 ± 4

0.637

Male sex, n (%)

122 (68)

49 (88)

64 (57)

4 (67)

5 (100)

< 0.001

Blood biomarkers

 LDH, IU/L

218 ± 73.7

211.6 ± 54.9

222.1 ± 83.2

243.8 ± 58.2

188.2 ± 25.4

0.181

 SP-D, ng/mL

197.9 ± 240.1

170.1 ± 140.9

208.2 ± 259.7

377.7 ± 517.4

63.5 ± 27.2

0.097

 KL-6, U/mL

843.1 ± 1090.4

727.4 ± 435.1

808.4 ± 1030.8

2692 ± 3265.3

405.3 ± 154.4

0.118

 Monocyte ratio, %

8.6 ± 2.8

8.3 ± 2.2

8.7 ± 2.8

10.0 ± 5.9

7.3 ± 2.2

0.701

 Monocyte count, /μL

573.9 ± 226.1

627.0 ± 250.5

555.3 ± 211.8

537.8 ± 170.3

437.7 ± 237.0

0.290

Pulmonary function tests

 FVC, %predicted

94.2 ± 18.8

93.4 ± 18.7

94.2 ± 19.3

92.8 ± 10.8

105 ± 19.6

0.397

 D_Lco, %predicted

92.9 ± 30.5

81.2 ± 27.9

98.2 ± 30.6

83.1 ± 17.6

118.9 ± 25.0

0.001

ILD-GAP score

1.4 ± 1.4

3 ± 0.9

0.6 ± 0.7

0.7 ± 0.5

3.2 ± 0.4

< 0.001

HRCT score

 Honeycomb score, points

0.7 ± 1.8

1.8 ± 2.7

0.2 ± 0.8

0.3 ± 0.8

0

< 0.001

 GGO score, points

4.7 ± 2.9

5.2 ± 2.5

4.4 ± 2.5

8.2 ± 8.2

3.0 ± 1.0

0.064

Treatment

 Anti-fibrotic agents, n (%)

10 (5)

9 (16)

1 (1)

0 (0)

0 (0)

0.001

 Corticosteroid, n (%)

39 (22)

9 (16)

29 (26)

1 (17)

0 (0)

0.300

 Immunosuppressant, n (%)

21 (12)

1 (2)

20 (18)

0 (0)

0 (0)

0.003

Outcome

 Follow-up, days

679 ± 337

652 ± 329

697 ± 347

775 ± 294

484 ± 211

0.410

 3-y ILD-related events, n (%)

21 (12)

10 (18)

10 (9)

0 (0)

1 (20)

0.261